These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2101518)

  • 1. [Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case].
    Cucé LC; Belda Júnior W; Dias MC
    Rev Inst Med Trop Sao Paulo; 1990; 32(4):249-51. PubMed ID: 2101518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
    Rodrigues ML; Costa RS; Souza CS; Foss NT; Roselino AM
    Rev Inst Med Trop Sao Paulo; 1999; 41(1):33-7. PubMed ID: 10436668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
    Castro C; Sampaio RN; Marsden PD
    Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
    [No Abstract]   [Full Text] [Related]  

  • 4. [A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].
    Oliveira MC; Amorim RF; Freitas Rde A; Costa Ade L
    Rev Soc Bras Med Trop; 2005; 38(3):258-60. PubMed ID: 15895180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report].
    Matoussi N; Ameur HB; Amor SB; Fitouri Z; Becher SB
    Med Mal Infect; 2007 Dec; 37 Suppl 3():S257-9. PubMed ID: 18054189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug hypersensitivity syndrome induced by meglumine antimoniate.
    Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
    Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Meglumine antimoniate].
    Silva JB
    Rev Soc Bras Med Trop; 2001; 34(1):103-5. PubMed ID: 11340506
    [No Abstract]   [Full Text] [Related]  

  • 8. [Symptomatic hypokalemia caused by meglumine antimoniate].
    Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
    Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
    [No Abstract]   [Full Text] [Related]  

  • 9. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure.
    Marques SA; Merlotto MR; Ramos PM; Marques MEA
    An Bras Dermatol; 2019 Jul; 94(3):355-357. PubMed ID: 31365669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentavalent antimonial-induced torsade de pointes.
    Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
    J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
    Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
    Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First report on ototoxicity of meglumine antimoniate.
    Valete-Rosalino CM; Araujo-Melo MH; Bezerra DC; Barcelos RO; Melo-Ferreira Vd; Torraca TS; Martins AC; Moreira JS; Vargas MC; Braga FP; Salgueiro Mde M; Saheki MN; Schubach AO
    Rev Inst Med Trop Sao Paulo; 2014; 56(5):439-42. PubMed ID: 25229226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
    Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
    Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of urticaria during pentavalent antimony use in a patient with mucous leishmaniasis].
    Oliveira MR; Marsden PD
    Rev Soc Bras Med Trop; 1995; 28(3):287. PubMed ID: 7480927
    [No Abstract]   [Full Text] [Related]  

  • 15. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
    Segura I; García-Bolao I
    Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
    Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
    Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Torsade de pointes secondary to treatment with pentavalent antimonial drugs].
    Temprano Vázquez S; García Salazar MA; Jiménez Martín MJ; López Martínez J
    Med Clin (Barc); 1998 May; 110(18):717. PubMed ID: 9656226
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
    Lambertucci JR; França BM; Queiroz Ede M
    Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
    Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
    Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.